Prescribing for different antibiotic classes across age groups in the Kaiser Permanente Northern California population in association with influenza incidence, 2010-2018.


Journal

Epidemiology and infection
ISSN: 1469-4409
Titre abrégé: Epidemiol Infect
Pays: England
ID NLM: 8703737

Informations de publication

Date de publication:
26 10 2022
Historique:
pubmed: 27 10 2022
medline: 18 11 2022
entrez: 26 10 2022
Statut: epublish

Résumé

There is limited information on the volume of antibiotic prescribing that is influenza-associated, resulting from influenza infections and their complications (such as streptococcal pharyngitis). We estimated that for the Kaiser Permanente Northern California population during 2010-2018, 3.4% (2.8%-4%) of all macrolide prescriptions (fills), 2.7% (2.3%-3.2%) of all aminopenicillin prescriptions, 3.1% (2.4%-3.9%) of all 3rd generation cephalosporins prescriptions, 2.2% (1.8%-2.6%) of all protected aminopenicillin prescriptions and 1.3% (1%-1.6%) of all quinolone prescriptions were influenza-associated. The corresponding proportions were higher for select age groups, e.g. 4.3% of macrolide prescribing in ages over 50 years, 5.1% (3.3%-6.8%) of aminopenicillin prescribing in ages 5-17 years and 3.3% (1.9%-4.6%) in ages <5 years was influenza-associated. The relative contribution of influenza to antibiotic prescribing for respiratory diagnoses without a bacterial indication in ages over 5 years was higher than the corresponding relative contribution to prescribing for all diagnoses. Our results suggest a modest benefit of increasing influenza vaccination coverage for reducing prescribing for the five studied antibiotic classes, particularly for macrolides in ages over 50 years and aminopenicillins in ages <18 years, and the potential benefit of other measures to reduce unnecessary antibiotic prescribing for respiratory diagnoses with no bacterial indication, both of which may contribute to the mitigation of antimicrobial resistance.

Identifiants

pubmed: 36285506
doi: 10.1017/S0950268822001662
pii: S0950268822001662
pmc: PMC9987027
doi:

Substances chimiques

Anti-Bacterial Agents 0
Macrolides 0
Penicillins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e180

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : NIGMS NIH HHS
ID : U54 GM088558
Pays : United States
Organisme : Wellcome Trust
ID : 219759/Z/19/Z
Pays : United Kingdom

Références

N Engl J Med. 1999 Jan 28;340(4):260-4
pubmed: 9920949
Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):12896-12901
pubmed: 30559195
J Antimicrob Chemother. 2014 Jan;69(1):234-40
pubmed: 23887867
J Antimicrob Chemother. 2009 Jul;64(1):169-74
pubmed: 19435736
Infect Dis Ther. 2018 Mar;7(1):171-174
pubmed: 29273976
J Antimicrob Chemother. 2021 Oct 11;76(11):2745-2747
pubmed: 34297821
Perm J. 2016 Fall;20(4):15-225
pubmed: 27548806
Ann Intern Med. 2017 Jun 06;166(11):765-774
pubmed: 28492914
Clin Infect Dis. 2016 Jul 1;63(1):21-32
pubmed: 27025838
Antimicrob Agents Chemother. 2017 Apr 24;61(5):
pubmed: 28193660
Vaccine. 2007 Feb 19;25(9):1683-9
pubmed: 17156899
Int J Antimicrob Agents. 2019 Jul;54(1):23-34
pubmed: 30851403
JAMA Netw Open. 2018 Jun 1;1(2):e180243
pubmed: 30646067
Epidemiology. 2012 Nov;23(6):829-38
pubmed: 22992574
EGEMS (Wash DC). 2014 Mar 24;2(1):1049
pubmed: 25848584
Open Forum Infect Dis. 2021 Feb 04;8(7):ofab063
pubmed: 34250183
Clin Infect Dis. 2021 Jun 15;72(12):2144-2153
pubmed: 32270199
Open Forum Infect Dis. 2020 Feb 26;7(3):ofaa065
pubmed: 32195289
Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-e67
pubmed: 31573350
JAMA. 2016 May 3;315(17):1864-73
pubmed: 27139059
Epidemiol Infect. 2022 Feb 24;150:e85
pubmed: 35506177
Am J Epidemiol. 2014 Jan 15;179(2):156-67
pubmed: 24190951
Infect Control Hosp Epidemiol. 2022 May;43(5):651-653
pubmed: 34078495
Proc Natl Acad Sci U S A. 2014 Nov 4;111(44):15798-803
pubmed: 25331901
Antimicrob Agents Chemother. 2016 Apr 22;60(5):3170-3
pubmed: 26926640
PLoS Med. 2020 Aug 19;17(8):e1003208
pubmed: 32813708

Auteurs

Edward Goldstein (E)

Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115 USA.

Bruce H Fireman (BH)

Kaiser Permanente Division of Research, Oakland, CA 94612 USA.

Nicola P Klein (NP)

Kaiser Permanente Division of Research, Oakland, CA 94612 USA.
Kaiser Permanente Division of Research, Vaccine Study Center, Oakland, CA 94612 USA.

Marc Lipsitch (M)

Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115 USA.
Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115 USA.

G Thomas Ray (GT)

Kaiser Permanente Division of Research, Oakland, CA 94612 USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH